All In Biotech

Drug Trial Radar · NCT07868926

Absorption, Distribution, Metabolism, and Excretion of 14C-VX-407 After a Single Oral Dose

A Phase 1, Open-Label, Mass Balance Study to Investigate the Absorption, Distribution, Metabolism, and Excretion of 14C-VX-407 Following Single Oral Administration in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

8

Planned (sponsor's estimate)

Start

Oct 16, 2026

Primary completion

Dec 15, 2026

Study completion Dec 15, 2026

Sponsor

Lead sponsor
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
Sponsor type
Industry
First posted
Oct 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 19 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the pharmacokinetics, safety and tolerability of VX-407 following a single oral dose.

Conditions

  • Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Interventions

  • 14C-VX-407Drug

    Solution for Oral Administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Amount of Radioactivity Excreted (Ae) of 14C-VX-407 Total Radioactivity (TRA) in Urine, and FecesTime frame: From Day -1 up to Day 30
  2. Terminal Phase Rate Constant (λz) of VX-407 in PlasmaTime frame: From Day 1 up to Day 30
  3. Area Under the Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUC0-tlast) of VX-407 in PlasmaTime frame: From Day 1 up to Day 30
  4. Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of VX-407 in PlasmaTime frame: From Day 1 up to Day 30
  5. Apparent Clearance (CL/F) of VX-407 in PlasmaTime frame: From Day 1 up to Day 30
  6. Renal Clearance (CLr) of VX-407Time frame: From Day -1 up to Day 30
  7. Maximum Observed Plasma Concentration (Cmax) of VX-407 in PlasmaTime frame: From Day 1 up to Day 30
  8. Time for VX-407 to Reach Maximum Concentration (Tmax) of VX-407 in Plasma and UrineTime frame: From Day 1 up to Day 30
  9. Fraction (percent) of Dose Excreted Unchanged in Urine of VX-407 (fe)Time frame: From Day -1 up to Day 30
  10. Apparent Volume of Distribution (Vz/F) (Based on the Terminal Phase) of VX-407 in PlasmaTime frame: From Day 1 up to Day 30
  11. Terminal Phase Rate Constant (λz) of Total Radioactivity (TRA) in Whole blood and PlasmaTime frame: From Day 1 up to Day 30
  12. AUC0-tlast of TRA in Whole blood and PlasmaTime frame: From Day 1 up to Day 30
  13. AUC0-inf of TRA in Whole blood and PlasmaTime frame: From Day 1 up to Day 30
  14. CL/F of TRA in Whole blood and PlasmaTime frame: From Day 1 up to Day 30
  15. Cmax of TRA in Whole blood and PlasmaTime frame: From Day 1 up to Day 30
  16. Fraction (percent) of Dose Excreted Unchanged in Urine of TRATime frame: From Day -1 up to Day 30
  17. Apparent Volume of Distribution (Based on the Terminal Phase) of TRA in Whole blood and PlasmaTime frame: From Day 1 up to Day 30

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Celerion - Lincoln

    Lincoln, Nebraska · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.